Marta M Alonso

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5994340/publications.pdf

Version: 2024-02-01

152 papers	5,661 citations	87888 38 h-index	82547 72 g-index
155 all docs	155 docs citations	155 times ranked	10673 citing authors

#	Article	IF	Citations
1	The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro. International Journal of Molecular Sciences, 2022, 23, 2001.	4.1	4
2	Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. JCI Insight, 2022, 7, .	5.0	14
3	Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory. Molecular Cancer Therapeutics, 2022, 21, 471-480.	4.1	6
4	Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality. Frontiers in Immunology, 2022, 13, 866892.	4.8	5
5	The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies. Neuro-Oncology, 2022, 24, 1408-1422.	1.2	27
6	Different Effects of Valproic Acid on SLC12A2, SLC12A5 and SLC5A8 Gene Expression in Pediatric Glioblastoma Cells as an Approach to Personalised Therapy. Biomedicines, 2022, 10, 968.	3.2	3
7	DIPG-22. Modifying the tumor microenvironment with a TIM-3 monoclonal antibody as a therapeutic strategy for DIPGs. Neuro-Oncology, 2022, 24, i22-i23.	1.2	1
8	IMMU-18. Targeting Antigen Presenting Cells to improve virotherapy efficacy in Diffuse Midline Gliomas. Neuro-Oncology, 2022, 24, i85-i85.	1.2	0
9	Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. New England Journal of Medicine, 2022, 386, 2471-2481.	27.0	102
10	Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma. Molecular Therapy - Oncolytics, 2021, 20, 23-33.	4.4	2
11	The Effectiveness of Dichloroacetate on Human Glioblastoma Xenograft Growth Depends on Na+ and Mg2+ Cations. Dose-Response, 2021, 19, 155932582199016.	1.6	3
12	Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy. , 2021, 9, e002086.		23
13	IMMU-06. DELTA-24-RGD EXPRESSING POSITIVE IMMUNE MODULATORS SHOW ANTI-DIPG EFFECT AND INCREASE TUMOR IMMUNE INFILTRATION. Neuro-Oncology, 2021, 23, i28-i28.	1.2	0
14	IMMU-01. THE ONCOLYTIC VIRUS DELTA-24-RGD IN COMBINATION WITH AN AGONISTIC CD40 MAB INDUCES A DURABLE AND SYNERGISTIC ANTI-TUMOR IMMUNE EFFECT IN DIPG PRECLINICAL MODELS. Neuro-Oncology, 2021, 23, i26-i27.	1.2	0
15	HGG-15. THE IMIPRIDONE ONC201 IN COMBINATION WITH THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD HAS A SYNERGISTIC EFFECT IN PRECLINICAL MODELS OF PHGGS AND DMGS. Neuro-Oncology, 2021, 23, i20-i20.	1.2	0
16	EPCT-04. RESULTS OF A PHASE 1 STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 WITH RADIOTHERAPY FOR NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). Neuro-Oncology, 2021, 23, i47-i47.	1.2	1
17	IMMU-09. MODULATING THE MYELOID POPULATION IN DIPG MODELS WITH ONCOLYTIC VIRUS AND COMPLEMENT INHIBITORS SHOWS THERAPEUTIC EFFICACY. Neuro-Oncology, 2021, 23, i28-i29.	1.2	0
18	IMMU-08. MICROENVIRONMENT MODULATION BY TIM-3 BLOCKADE IMPROVES THE OUTCOME OF PRECLINICAL DIPG MODELS. Neuro-Oncology, 2021, 23, i28-i28.	1.2	0

#	Article	IF	Citations
19	Abstract 3053: Armed oncolytic virus for treatment of pediatric diffuse intrinsic pontine glioma. , 2021, , .		0
20	CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models. , 2021, 9, e002644.		25
21	Hitchhiking to brain tumours: stem cell delivery of oncolytic viruses. Lancet Oncology, The, 2021, 22, 1049-1051.	10.7	6
22	Identification of a Dexamethasone Mediated Radioprotection Mechanism Reveals New Therapeutic Vulnerabilities in Glioblastoma. Cancers, 2021, 13, 361.	3.7	8
23	Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET. Clinical Cancer Research, 2021, 27, 1807-1820.	7.0	12
24	Clinical Value of NGS Genomic Studies for Clinical Management of Pediatric and Young Adult Bone Sarcomas. Cancers, 2021, 13, 5436.	3.7	4
25	Sarcoma treatment in the era of molecular medicine. EMBO Molecular Medicine, 2020, 12, e11131.	6.9	154
26	RNU6-1 in circulating exosomes differentiates GBM from non-neoplastic brain lesions and PCNSL but not from brain metastases. Neuro-Oncology Advances, 2020, 2, vdaa010.	0.7	11
27	Immunotherapy with CAR-T cells in paediatric haematology-oncology. Anales De PediatrÃa (English) Tj ETQq1 1 0.784314 rgBT /Overlock	0.2	0
28	Somatic and germline analysis of a familial Rothmundâ€“Thomson syndrome in two siblings with osteosarcoma. Npj Genomic Medicine, 2020, 5, 51.	3.8	3
29	THER-09. ONCOLYTIC ADENOVIRUS, DNX-2401, FOR NAIVE DIFFUSE INTRINSIC PONTINE GLIOMAS: A PHASE I CLINICAL TRIAL. Neuro-Oncology, 2020, 22, iii473-iii473.	1.2	0
30	THER-01. AWAKING THE IMMUNE SYSTEM WITH AN IMMUNO-ONCOLYTIC VIRUS AS A THERAPEUTIC STRATEGY FOR DIPGs. Neuro-Oncology, 2020, 22, iii471-iii471.	1.2	0
31	THER-02. EVALUATION OF THE ONCOLYTIC VIRUS DELTA24-RGD AS AN ANTI-TUMOR AGENT IN PRECLINICAL MODELS OF LOCALIZED AND DISSEMINATED AT/RT. Neuro-Oncology, 2020, 22, iii471-iii471.	1.2	0
32	miR-425-5p, a SOX2 target, regulates the expression of FOXJ3 and RAB31 and promotes the survival of GSCs. Archives of Clinical and Biomedical Research, 2020, 04, 221-238.	0.2	6
33	IMMU-14. ONCOLYTIC ADENOVIRUS DELTA-24-RGD ENGINEERED TO EXPRESS 4-1BBL AS A THERAPEUTIC APPROACH FOR DIPG. Neuro-Oncology, 2020, 22, ii107-ii107.	1.2	0
34	EXTH-39. HEXON SWAPPING MITIGATES ANTI-VIRAL IMMUNE RESPONSE DURING BRAIN TUMOR VIROTHERAPY. Neuro-Oncology, 2020, 22, ii95-ii95.	1.2	0
35	IMMU-39. TIM-3 APTAMER IN COMBINATION WITH RADIOTHERAPY RESULTS IN ENHANCED SURVIVAL IN DIPG MODELS. Neuro-Oncology, 2020, 22, ii113-ii113.	1.2	0
36	CTIM-25. ONCOLYTIC VIRUS FOR DIPG: THE CLINICAL EXPERIENCE WITH DNX-2401. Neuro-Oncology, 2020, 22, ii38-ii38.	1.2	0

#	Article	IF	Citations
37	IMMU-21. THE COMBINATION OF DELTA-24-ACT WITH AN IMMUNE CHECKPOINT INHIBITOR RESULTS IN ANTI-GLIOMA EFFECT AND IMMUNE MEMORY. Neuro-Oncology, 2020, 22, ii109-ii109.	1.2	0
38	EXTH-60. CHARACTERIZATION OF THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD AS THERAPEUTIC AGENT FOR THE TREATMENT OF THE PEDIATRIC EMBRYONAL BRAIN TUMORS AT/RT AND CNS-PNET. Neuro-Oncology, 2020, 22, ii100-ii100.	1.2	0
39	The Importance of Gender-Related Anticancer Research on Mitochondrial Regulator Sodium Dichloroacetate in Preclinical Studies In Vivo. Cancers, 2019, 11, 1210.	3.7	9
40	The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models. Scientific Reports, 2019, 9, 14368.	3.3	10
41	THER-25. IMMUNE ONCOLYTIC ADENOVIRUS FOR DIPG TREATMENT. Neuro-Oncology, 2019, 21, ii119-ii119.	1.2	0
42	OS5.1 Phase I clinical trial with oncolytic virus DNX-2401 for DIPGs. Neuro-Oncology, 2019, 21, iii11-iii11.	1.2	1
43	P06.01 Delta24-ACT oncolytic adenovirus as a therapeutic approach for DIPG. Neuro-Oncology, 2019, 21, iii36-iii36.	1.2	0
44	Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas. Clinical Cancer Research, 2019, 25, 6801-6814.	7.0	27
45	GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory. Neuro-Oncology Advances, 2019, 1, vdz009.	0.7	21
46	The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nature Communications, 2019, 10, 2235.	12.8	96
47	DIPG-04. TRANSLATION OF DNX-2401 FROM THE BENCH TO THE CLINIC FOR PEDIATRIC HIGH GRADE GLIOMAS INCLUDING DIFFUSE INTRINSIC PONTINE GLIOMAS. Neuro-Oncology, 2019, 21, ii68-ii69.	1.2	0
48	ATRT-03. EFFICACY OF THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD AS A THERAPEUTIC AGENT FOR THE TREATMENT OF PEDIATRIC EMBRYONAL BRAIN TUMORS. Neuro-Oncology, 2019, 21, ii63-ii63.	1.2	0
49	Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models. Acta Neuropathologica Communications, 2019, 7, 64.	5.2	31
50	PDTM-23. DELTA-24-RGD ONCOLYTIC ADENOVIRUS MEDIATES ANTI-TUMOR EFFECT IN LOCALIZED AND DISSEMINATED AT/RT MURINE MODELS. Neuro-Oncology, 2019, 21, vi192-vi192.	1.2	0
51	EXTH-27. ACTIVATING THE IMMUNITY WITHIN THE TUMOR USING VIROIMMUNOTHERAPY: DELTA-24-RGD ONCOLYTIC ADENOVIRUS ARMED WITH THE IMMUNOPOSITIVE REGULATOR GITRL. Neuro-Oncology, 2019, 21, vi87-vi87.	1.2	0
52	EXTH-11. TREATMENT WITH DELTA-24-RGDOX OF SUBCUTANEOUS TUMORS RESULTS IN ABSCOPAL EFFECT ERADICATING INTRACRANIAL MELANOMAS. Neuro-Oncology, 2019, 21, vi84-vi84.	1.2	0
53	IMMU-14. ONCOLYTIC VIRUS EXPRESSING A POSITIVE IMMUNE CHECKPOINT MODULATOR AS A THERAPEUTIC APPROACH FOR DIPG. Neuro-Oncology, 2019, 21, vi122-vi122.	1.2	0
54	PDCT-18 (LTBK-03). PHASE I CLINICAL TRIAL WITH ONCOLYTIC VIRUS DNX-2401 FOR DIPGS. Neuro-Oncology, 2019, 21, vi283-vi284.	1.2	0

#	Article	IF	Citations
55	P11.23 Oncolytic adenovirus Delta-24-RGD exerts a potent anti-tumor effect in preclinical models of atypical teratoid/rhabdoid tumors. Neuro-Oncology, 2019, 21, iii47-iii47.	1.2	0
56	Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy. Journal of Proteomics, 2019, 194, 168-178.	2.4	8
57	Destress and do not suppress: targeting adrenergic signaling in tumor immunosuppression. Journal of Clinical Investigation, 2019, 129, 5086-5088.	8.2	10
58	Abstract 3117: Delta-24-RGD/DNX-2401: Oncolytic virotherapy for pediatric high grade glioma and DIPG. , 2019, , .		0
59	Abstract 3115: High-capacity adenoviral vectors with controlled expression of interleukin 12 as a new strategy against pediatric osteosarcoma. , 2019, , .		0
60	Linking inflammation and cancer: the unexpected SYK world. Neuro-Oncology, 2018, 20, 582-583.	1.2	13
61	The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma. Neuro-Oncology, 2018, 20, 930-941.	1.2	29
62	Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients. Neurosurgery, 2018, 83, 1050-1056.	1.1	40
63	Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors. OncoImmunology, 2018, 7, e1450711.	4.6	3
64	SEOM clinical guidelines for anaplastic gliomas (2017). Clinical and Translational Oncology, 2018, 20, 16-21.	2.4	12
65	Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. Journal of Clinical Oncology, 2018, 36, 1419-1427.	1.6	477
66	CBMT-19. RNU6-1 ANALYSED IN EXOSOMES FROM SERA AS A NOVEL DIFFERENTIAL BIOMARKER FOR GBM VS NON-NEOPLASTIC BRAIN LESIONS AND NSCPL. Neuro-Oncology, 2018, 20, vi36-vi36.	1.2	0
67	Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models by [18F]FDG and sodium [18F]fluoride PET. BMC Cancer, 2018, 18, 1193.	2.6	11
68	Basic and Translational Advances in Glioblastoma. BioMed Research International, 2018, 2018, 1-2.	1.9	7
69	DNX-2401, an Oncolytic Virus, for the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Gliomas: A Case Report. Frontiers in Oncology, 2018, 8, 61.	2.8	42
70	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
71	Oncolytic Viruses as Therapeutic Tools for Pediatric Brain Tumors. Cancers, 2018, 10, 226.	3.7	23
72	Oncolytic Virotherapy for Gliomas. , 2018, , 357-384.		4

#	Article	IF	Citations
73	Spatial and temporal proteome dynamics of glioma cells during oncolytic adenovirus Delta-24-RGD infection. Oncotarget, 2018, 9, 31045-31065.	1.8	8
74	Abstract 3192: Aptamers, antibodies and radiotherapy for the treatment of DIPG. , 2018, , .		0
75	Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope. Journal of Bone Oncology, 2017, 9, 41-47.	2.4	21
76	A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. Journal of Translational Medicine, 2017, 15, 104.	4.4	100
77	A new species of Chionoloma (Pottiaceae) from Central and South America with a key to Neotropical species of the genus. Bryologist, 2017, 120, 340-346.	0.6	8
78	IMMU-03. COMBINATION OF RADIOTHERAPY WITH AÂ4-1BB AGONIST ANTIBODY AND AÂTIM-3 APTAMER RESULTS IN ENHANCED SURVIVAL IN AÂDIPG MODEL. Neuro-Oncology, 2017, 19, iv28-iv28.	1.2	0
79	GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. Cell Reports, 2017, 21, 2183-2197.	6.4	56
80	CBIO-06. POTENTIAL ROLE OF RNU6 ISOLATED FROM CIRCULATING EXOSOMES AS AÂDIAGNOSTIC BIOMARKER FOR GLIOBLASTOMA. Neuro-Oncology, 2017, 19, vi33-vi34.	1.2	0
81	PDTM-12. THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD MEDIATES AN EFFICIENT ANTITUMOR RESPONSE IN VIVO IN SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMORS. Neuro-Oncology, 2017, 19, vi192-vi192.	1.2	0
82	IMMU-39. COMBINATION OF RADIOTHERAPY WITH AÂ4-1BB AGONIST ANTIBODY AND AÂTIM-3 APTAMER RESULTS IN ENHANCED SURVIVAL IN AÂDIPG MODEL. Neuro-Oncology, 2017, 19, vi121-vi121.	1.2	0
83	DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients. Oncotarget, 2017, 8, 1416-1428.	1.8	193
84	ATIM-08. IMMUNOMARKERS IN THE DNX-2401 (DELTA-24-RGD) ONCOLYTIC VIRUS PHASE IÂCLINICAL TRIAL. Neuro-Oncology, 2017, 19, vi27-vi27.	1.2	3
85	MEDU-21. TREATMENT OF PNETS WITH THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD RESULTS IN ANTITUMOR EFFECT. Neuro-Oncology, 2017, 19, iv42-iv42.	1.2	0
86	Abstract CT027: Oncolytic virus DNX-2401 with a short course of temozolomide for glioblastoma at first recurrence: Clinical data and prognostic biomarkers. Cancer Research, 2017, 77, CT027-CT027.	0.9	17
87	Development of a DIPG Orthotopic Model in Mice Using an Implantable Guide-Screw System. PLoS ONE, 2017, 12, e0170501.	2.5	11
88	Abstract LB-235: Delta-24-RGD oncolytic adenovirus treatment downmodulates the key regulator of T-cell exhaustion TIM3 in malignant gliomas. , 2017, , .		0
89	Abstract 704: Therapeutic potential of Delta24-ACT, a novel immunostimulatory oncolytic adenovirus, for the treatment of pediatric solid tumors: Initial study in pHGG, DIPG and osteosarcoma. , 2017, , .		0
90	ACTR-15. AÂPHASE IÂSTUDY OF THE ONCOLYTIC VIRUS DNX-2401 AND AÂSHORT COURSE TEMOZOLOMIDE FOR GLIOBLASTOMA AT FIRST RECURRENCE. Neuro-Oncology, 2016, 18, vi4-vi4.	1.2	3

#	Article	IF	Citations
91	HG-51DELTA-24-RDG IN COMBINATION WITH RADIOTHERAPY FOR DIPG: OPENING NEW THERAPEUTIC AVENUES. Neuro-Oncology, 2016, 18, iii58.4-iii59.	1.2	1
92	Conditionally Replicative Adenovirusesâ€"Clinical Trials. , 2016, , 335-348.		1
93	Critical Role of Autophagy in the Processing of Adenovirus Capsid-Incorporated Cancer-Specific Antigens. PLoS ONE, 2016, 11, e0153814.	2.5	19
94	EXTH-09. LOOKING FOR AÂCURE: DELTA-24-RDG AND RADIOTHERAPY FOR DIPG TREATMENT. Neuro-Oncology, 2016, 18, vi61-vi61.	1.2	1
95	PCM-14DEVELOPMENT OF A NEW DIPG ORTHOTOPIC MODEL IN MICE USING AN IMPLANTABLE GUIDED-SCREW SYSTEM. Neuro-Oncology, 2016, 18, iii142.1-iii142.	1.2	0
96	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	1.6	160
97	The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma. Clinical Cancer Research, 2016, 22, 2217-2225.	7.0	38
98	Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression. Oncogene, 2016, 35, 4719-4729.	5.9	27
99	Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51. Neuro-Oncology, 2016, 18, 1109-1119.	1.2	42
100	Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01. PLoS ONE, 2016, 11, e0147211.	2.5	31
101	Analysis of SOX2-Regulated Transcriptome in Glioma Stem Cells. PLoS ONE, 2016, 11, e0163155.	2.5	12
102	Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas. Oncotarget, 2016, 7, 16146-16157.	1.8	29
103	Salinomycin induced ROS results in abortive autophagy and leads to regulated necrosis in glioblastoma. Oncotarget, 2016, 7, 30626-30641.	1.8	55
104	C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy. Oncogene, 2015, 34, 5295-5301.	5.9	43
105	The nuclear receptor NR2E1/TLX controls senescence. Oncogene, 2015, 34, 4069-4077.	5.9	28
106	Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature Medicine, 2015, 21, 555-559.	30.7	473
107	The Oncolytic Adenovirus Î"24-RGD in Combination With Cisplatin Exerts a Potent Anti-Osteosarcoma Activity. Journal of Bone and Mineral Research, 2014, 29, 2287-2296.	2.8	26
108	A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro-Oncology, 2014, 16, 520-527.	1.2	298

#	Article	IF	Citations
109	ME-05 * COUNTERATTACKING THE FORCE BEHIND GLIOMA INVASION. Neuro-Oncology, 2014, 16, v120-v120.	1.2	0
110	Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget, 2014, 5, 2208-2220.	1.8	108
111	Role of SOX family of transcription factors in central nervous system tumors. American Journal of Cancer Research, 2014, 4, 312-24.	1.4	42
112	Involvement of miRNAs in the Differentiation of Human Glioblastoma Multiforme Stem-Like Cells. PLoS ONE, 2013, 8, e77098.	2.5	64
113	Targeting Brain Tumor Stem Cells with Oncolytic Adenoviruses. Methods in Molecular Biology, 2012, 797, 111-125.	0.9	22
114	PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia, 2011, 25, 606-614.	7.2	124
115	MicroRNA-451 Is Involved in the Self-renewal, Tumorigenicity, and Chemoresistance of Colorectal Cancer Stem Cells. Stem Cells, 2011, 29, 1661-1671.	3.2	248
116	Malignant Gliomas: Role of E2F1 Transcription Factor. , 2011, , 89-97.		2
117	Genetic and Epigenetic Modifications of Sox2 Contribute to the Invasive Phenotype of Malignant Gliomas. PLoS ONE, 2011, 6, e26740.	2.5	187
118	Abstract 5402: Enhancing autophagy as a novel approach to target osteosarcoma: combination of Oncolytic adenovirus and chemotherapy. , 2011, , .		1
119	Abstract 3307: The multitasking of Sox2: Maintaining the stemness and inducing the malignant phenotype of gliomas. , 2011, , .		0
120	EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2. British Journal of Cancer, 2010, 103, 1292-1296.	6.4	33
121	The RB-E2F1 Pathway Regulates Autophagy. Cancer Research, 2010, 70, 7882-7893.	0.9	107
122	RB-E2F1. Autophagy, 2010, 6, 1216-1217.	9.1	13
123	Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype. Oncotarget, 2010, 1, 700-9.	1.8	37
124	Tie2/TEK Modulates the Interaction of Glioma and Brain Tumor Stem Cells with Endothelial Cells and Promotes an Invasive Phenotype. Oncotarget, 2010, 1, 700-709.	1.8	56
125	Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Therapy, 2009, 16, 256-265.	4.6	42
126	Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters. Oncogene, 2009, 28, 2358-2363.	5.9	48

#	Article	IF	Citations
127	Estradiol induces type 8 17Î²-hydroxysteroid dehydrogenase expression: crosstalk between estrogen receptor Î± and C/EBPÎ². Journal of Endocrinology, 2009, 200, 85-92.	2.6	20
128	Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1Î± levels in gliomas. Oncogene, 2008, 27, 1310-1314.	5.9	17
129	E2F1 in gliomas: A paradigm of oncogene addiction. Cancer Letters, 2008, 263, 157-163.	7.2	42
130	Delta-24-RGD in Combination With RAD001 Induces Enhanced Anti-glioma Effect via Autophagic Cell Death. Molecular Therapy, 2008, 16, 487-493.	8.2	105
131	Interspecies adenovirus fiber shows "evolutionary" advantage for oncolytic therapy of gliomas. Cancer Biology and Therapy, 2008, 7, 794-796.	3.4	0
132	Examination of the Therapeutic Potential of Delta-24-RGD in Brain Tumor Stem Cells: Role of Autophagic Cell Death. Journal of the National Cancer Institute, 2007, 99, 1410-1414.	6.3	268
133	Cell Cycleâ€“Dependent Nuclear Export of Phosphatase and Tensin Homologue Tumor Suppressor Is Regulated by the Phosphoinositide-3-Kinase Signaling Cascade. Cancer Research, 2007, 67, 11054-11063.	0.9	45
134	Transgenic E2F1 Expression in the Mouse Brain Induces a Human-Like Bimodal Pattern of Tumors. Cancer Research, 2007, 67, 4005-4009.	0.9	29
135	ICOVIR-5 Shows E2F1 Addiction and Potent Antiglioma Effect In vivo. Cancer Research, 2007, 67, 8255-8263.	0.9	63
136	Adenovirus-Based Strategies Overcome Temozolomide Resistance by Silencing the O6-Methylguanine-DNA Methyltransferase Promoter. Cancer Research, 2007, 67, 11499-11504.	0.9	130
137	Transcriptional regulation of the human type 8 17Î²-hydroxysteroid dehydrogenase gene by C/EBPÎ². Journal of Steroid Biochemistry and Molecular Biology, 2007, 105, 131-139.	2.5	19
138	Systemic Toxicityâ€“Efficacy Profile of ICOVIR-5, a Potent and Selective Oncolytic Adenovirus Based on the pRB Pathway. Molecular Therapy, 2007, 15, 1607-1615.	8.2	84
139	Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Therapy, 2007, 14, 756-761.	4.6	61
140	Sustained Angiopoietin-2 Expression Disrupts Vessel Formation and Inhibits Glioma Growth. Neoplasia, 2006, 8, 419-428.	5.3	38
141	E2F1 and Telomerase: Alliance in the Dark Side. Cell Cycle, 2006, 5, 930-935.	2.6	22
142	Expression of the Receptor Tyrosine Kinase Tie2 in Neoplastic Glial Cells Is Associated with Integrin Î²1-Dependent Adhesion to the Extracellular Matrix. Molecular Cancer Research, 2006, 4, 915-926.	3.4	67
143	Delta-24 Increases the Expression and Activity of Topoisomerase I and Enhances the Antiglioma Effect of Irinotecan. Clinical Cancer Research, 2006, 12, 556-562.	7.0	51
144	A novel CRM1â€dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation. FASEB Journal, 2006, 20, 2603-2605.	0.5	10

#	Article	IF	Citations
145	320. Modeling Human Brain Cancer in Transgenic E2F1 Mice. Molecular Therapy, 2006, 13, S122.	8.2	0
146	Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. Expert Review of Anticancer Therapy, 2006, 6, 1585-1592.	2.4	26
147	Expression of Transcription Factor E2F1 and Telomerase in Glioblastomas: Mechanistic Linkage and Prognostic Significance. Journal of the National Cancer Institute, 2005, 97, 1589-1600.	6.3	57
148	Downmodulation of El A Protein Expression as a Novel Strategy to Design Cancer-Selective Adenoviruses. Neoplasia, 2005, 7, 723-729.	5.3	13
149	Comparative Effect of Oncolytic Adenoviruses with E1 A or E113-55 kDa Deletions in Malignant Gliomas. Neoplasia, 2005, 7, 48-56.	5.3	35
150	A novel E1Aâ€“E1B mutant adenovirus induces glioma regression in vivo. Oncogene, 2004, 23, 1821-1828.	5.9	60
151	New benzo(b)thiophenesulphonamide 1,1-dioxide derivatives induce a reactive oxygen species-mediated process of apoptosis in tumour cells. Oncogene, 2003, 22, 3759-3769.	5.9	26
152	New cytotoxic benzo(b)thiophenilsulfonamide 1,1-dioxide derivatives inhibit a NADH oxidase located in plasma membranes of tumour cells. British Journal of Cancer, 2001, 85, 1400-1402.	6.4	10